Restart Life Sciences Corp.

As of June 30, 2026, Restart Life Sciences Corp. carries a market capitalization of 5.30M, placing it among publicly traded companies globally. Its enterprise value stands at 4.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Restart Life Sciences Corp. has 62.36M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.40, and the price-to-book ratio stands at 4.00.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.89M versus a market cap of 5.30M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Restart Life Sciences Corp. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.30, indicating elevated leverage, while an interest coverage ratio of -79.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Restart Life Sciences Corp. posted a negative return on equity (ROE) of -246.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -156.90, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Restart Life Sciences Corp.'s stock has declined approximately 37.50% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.09.

Over the twelve months ended June 30, 2026, Restart Life Sciences Corp. generated 465,715.00 in revenue and converted that into -1.71M in net income, yielding earnings per share of -0.03. EBITDA reached -1.62M, while operating income came in at -1.70M.

As of June 30, 2026, Restart Life Sciences Corp. holds 762,363.00 in cash and equivalents against 348,345.00 in total debt, resulting in a net debt position of -329,102.00. Total book value stands at 1.32M, with working capital of 486,515.00 providing operational flexibility.

Restart Life Sciences Corp. produced -980,851.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -365.86 and net profit margin of -367.41 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Restart Life Sciences Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -22.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -45.21, meaning Restart Life Sciences Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Restart Life Sciences Corp.'s most recent stock split took place on January 29, 2025 with a 2:1 split ratio.

As of June 30, 2026, Restart Life Sciences Corp. has an Altman Z-Score of -75.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.